Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
This week's guest Joya Griffin, DVM, DACVD, discusses feline dermatology with host Adam Christman, DVM, MBA ...
Paris: Sanofi has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...
EMA committee recommends approval of Sanofi & Regeneron’s Dupixent to treat eosinophilic esophagitis in children as young as 1 year old: Paris Monday, September 23, 2024, 11:00 ...
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
Zacks.com on MSN6d
AZN Gets FDA Nod for Fasenra Label Expansion in Rare DiseaseThe FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback